HilleVax Files Q1 2025 10-Q
| Field | Detail |
|---|---|
| Company | Hillevax, Inc. |
| Form Type | 10-Q |
| Filed Date | May 8, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, biotech
TL;DR
HilleVax Q1 2025 10-Q filed. R&D expenses and equity plans detailed.
AI Summary
HilleVax, Inc. filed its 10-Q for the period ending March 31, 2025. The company, focused on biological products, reported financial data for the first quarter of 2025. Key financial activities and disclosures are detailed within this report, including information on research and development expenses and equity plans.
Why It Matters
This filing provides investors with an update on HilleVax's financial performance and operational status for the first quarter of 2025, crucial for assessing the company's trajectory.
Risk Assessment
Risk Level: medium — As a biotech company, HilleVax faces inherent risks related to drug development, regulatory approvals, and market competition, which are typical for the sector.
Key Numbers
- 20250331 — Reporting Period End Date (Indicates the end of the fiscal quarter for which the report is filed.)
- 20250508 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
- 2025-01-01 to 2025-03-31 — Q1 2025 Period (The specific timeframe covered by this quarterly report.)
Key Players & Entities
- HilleVax, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of reporting period
- 20250508 (date) — Filing date
- 321 HARRISON AVE, SUITE 500 (address) — Company's business and mailing address
- BOSTON (location) — Company's city
- MA (location) — Company's state
- 02118 (zip_code) — Company's zip code
- 001-41365 (sec_file_number) — SEC file number for HilleVax
- hlvx:LoanAndSecurityAgreementMember (document) — Mentioned agreement
- hlvx:ChengduKanghuaBiologicalProductsCoLtdMember (company) — Related entity
FAQ
What is the primary business of HilleVax, Inc.?
HilleVax, Inc. is primarily involved in the business of biological products, specifically excluding diagnostic substances, as indicated by its SIC code [2836].
What is the company's principal executive office location?
The company's principal executive office is located at 321 Harrison Ave, Suite 500, Boston, MA 02118.
What is the SEC file number for HilleVax, Inc.?
The SEC file number for HilleVax, Inc. is 001-41365.
What specific employee stock purchase plan is mentioned in the filing?
The filing mentions the 'TwoThousandTwentyTwoEmployeeStockPurchasePlanMember'.
What is the fiscal year end for HilleVax, Inc.?
The fiscal year end for HilleVax, Inc. is December 31 (1231).
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 8, 2025 regarding HilleVax, Inc..